peptide therapy cjc-1295 + ipamorelin & CJC-1295 / Ipamorelin Peptide Therapy:
Description
Ann N Y Acad Sci 2000;926:90100
Prenatal caffeine exposure: association with neurodevelopmental outcomes in 9 to 11 year old children
Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance
Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohns disease in the SONIC trial
Anthracyclines, taxanes or trastuzumab alone, at present, are not considered to be nephrotoxic, and current guidelines do not require dose reduction in patients with renal dysfunction
duBois RM
